A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

@article{Keilholz2009ACA,
  title={A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.},
  author={Ulrich Keilholz and Anne Letsch and Antonia Busse and Anne Marie Asemissen and Sandra S. Bauer and Igor Wolfgang Blau and Wolf-Karsten Hofmann and Lutz Uharek and Agnieszka Korfel and Carmen Scheibenbogen},
  journal={Blood},
  year={2009},
  volume={113 26},
  pages={
          6541-8
        }
}
This study investigated the immunogenicity of Wilms tumor gene product 1 (WT1)-peptide vaccination in WT1-expressing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients without curative treatment option. Vaccination consisted of granulocyte-macrophage colony-stimulating factor subcutaneously days 1 to 4, and WT1.126-134 peptide and 1 mg keyhole limpet hemocyanin on day 3. The initial 9 patients received 4 vaccinations biweekly, then monthly, and the subsequent 10 patients… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 139 CITATIONS, ESTIMATED 44% COVERAGE

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 9 Highly Influenced Citations

  • Averaged 7 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Cancer vaccines: moving beyond current paradigms.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2007

Similar Papers

Loading similar papers…